Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Alzamend Neuro Inc (NQ: ALZN )

1.645 +0.075 (+4.78%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alzamend Neuro Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Alzamend Neuro CEO Stephan Jackman to Appear on Fox Business Network to Discuss Therapeutic Pipeline
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Adds Healthy Subjects to Ongoing Mid-Stage Alzheimer's Trial
Via Benzinga
Alzamend Neuro Seeks FDA Nod For Dementia Immunotherapy Study
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! It's time to take a look at all of the latest news behind the biggest pre-market stock movers on Thursday! 
Via InvestorPlace
5.6 Million Bet On This Penny Stock? Check Out These 3 Penny Stocks Insiders Are Buying
The Nasdaq Composite closed lower by around 100 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
WaveDancer And 1 Other Stock Under $2 Insiders Are Aggressively Buying
The Dow Jones dropped by more than 600 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another overview of the biggest pre-market stock movers for Wednesday as we cover the news behind share movement this morning! 
Via InvestorPlace
Alzamend Neuro Receives Positive FDA Response For Its Depression Candidate
Via Benzinga
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
Via Benzinga
Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
From Alzamend Neuro, Inc.
Via Business Wire
Alzamend Neuro Submits IND Application for Phase I/IIA Trial for an Immunotherapy (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type
From Alzamend Neuro, Inc.
Via Business Wire
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028. 
Via Benzinga
Alzamend Neuro Stock Pops After Benzinga Exclusive On Cognition Therapeutics Alzheimer's Data
Shares of biopharmaceutical company Alzamend Neuro Inc (NASDAQ: ALZN) are soaring Thursday afternoon after Cognition Therapeutics Inc (NASDAQ: CGTX) shares surged following the presentation of a... 
Via Benzinga
6 Penny Stocks With 1,000% Upside Potential
Each of these penny stocks with 1,000% upside potential could rise 10X in the future for investors with a high risk tolerance. 
Via InvestorPlace
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational
From Alzamend Neuro, Inc.
Via Business Wire
4 Stocks Under $1 Insiders Are Aggressively Buying
The Nasdaq Composite jumped over 300 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder
From Alzamend Neuro, Inc.
Via Business Wire
Executives Buy Around $5M Of 4 Penny Stocks
US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the... 
Via Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:... 
Via Benzinga
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From Alzamend Neuro, Inc.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
From BitNile Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.